Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-09-15

FDA Approved: BREO ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for BREO ELLIPTA (fluticasone furoate and vilanterol) from GlaxoSmithKline, resulting in label changes and/or new indica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate)

Snippet

SUPPL AP for BREO ELLIPTA (FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE)